Novo Nordisk · 5 hours ago
Internship - RNAi Discovery
Lexington, MA
Internship
Onsite
Intern
$52K/yr - $89K/yrNovo Nordisk is a global pharmaceutical company that focuses on life science innovation. The RNAi Discovery intern will engage in experimental bench work to support the development of assays for measuring siRNA activity and potency, while collaborating with project scientists and maintaining laboratory records.
BiotechnologyHealth CareMedicalPharmaceutical
No H1B
Responsibilities
Perform routine and specialized cell culture techniques
Prepare assay reagents and controls
Plate and dose cells
Operate molecular based assay under supervision
Analyze experimental data
Generate summary figures and written reports
Participate in interpretation of results to guide assay improvements
Maintain laboratory records
Adhere to safety and quality standards
Collaborate with project scientists to refine protocols and troubleshoot technical issues
Qualification
Required
Must be a current student enrolled at an accredited college or university pursuing at least a bachelor's degree
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
An in progress graduate degree in Cell and Molecular Biology or a related discipline preferred
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
2026-02-09
Company data provided by crunchbase